Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
25.70
-0.60 (-2.28%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Bicara Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 12.96 | 9.27 | 6.34 |
| Research & Development | 45.38 | 30.62 | 31.31 |
| Operating Expenses | 58.34 | 39.89 | 37.66 |
| Operating Income | -58.34 | -39.89 | -37.66 |
| Interest Expense | - | - | -0.11 |
| Interest & Investment Income | 6.88 | 1.31 | 0 |
| Other Non Operating Income (Expenses) | -13.38 | -13.41 | -0.08 |
| Pretax Income | -64.84 | -51.98 | -37.84 |
| Income Tax Expense | 0.01 | 0.01 | 0 |
| Net Income | -64.84 | -51.99 | -37.85 |
| Net Income to Common | -64.84 | -51.99 | -37.85 |
| Shares Outstanding (Basic) | 1 | 1 | 0 |
| Shares Outstanding (Diluted) | 1 | 1 | 0 |
| Shares Change (YoY) | - | 35.20% | - |
| EPS (Basic) | -93.43 | -89.61 | -88.20 |
| EPS (Diluted) | -93.43 | -89.61 | -88.20 |
| Free Cash Flow | -46.67 | -46.21 | -32.27 |
| Free Cash Flow Per Share | -67.25 | -79.66 | -75.20 |
| EBITDA | -58.3 | -39.87 | -37.65 |
| D&A For EBITDA | 0.04 | 0.02 | 0.01 |
| EBIT | -58.34 | -39.89 | -37.66 |
Source: S&P Capital IQ. Standard template.
Financial Sources.